scholarly article | Q13442814 |
P50 | author | Atish D. Choudhury | Q58403143 |
David Liu | Q59751039 | ||
Haitham Elmarakeby | Q86928276 | ||
Jihye Park | Q88032960 | ||
William C Hahn | Q88192808 | ||
P2093 | author name string | Bose S Kochupurakkal | |
Eliezer M Van Allen | |||
Steven P Balk | |||
Mu-Yan Cai | |||
Justin H Hwang | |||
Kent W Mouw | |||
Shahrzad Rafiei | |||
Cora Ricker | |||
Kenyon Fitzpatrick | |||
P2860 | cites work | The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. | Q27851580 |
Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines | Q27853007 | ||
Integrative clinical genomics of advanced prostate cancer | Q27853170 | ||
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer | Q27853235 | ||
FirebrowseR: an R client to the Broad Institute's Firehose Pipeline | Q28583991 | ||
Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53 | Q36238650 | ||
Double-strand break repair by homologous recombination in primary mouse somatic cells requires BRCA1 but not the ATM kinase | Q36747534 | ||
Kinase-dead ATM protein is highly oncogenic and can be preferentially targeted by Topo-isomerase I inhibitors | Q37119667 | ||
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer | Q37179254 | ||
FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing | Q37264357 | ||
ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib | Q37633188 | ||
A synthetic lethal screen reveals enhanced sensitivity to ATR inhibitor treatment in mantle cell lymphoma with ATM loss-of-function | Q38955450 | ||
A double-strand break repair defect in ATM-deficient cells contributes to radiosensitivity | Q40595505 | ||
ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA Damage. | Q46518098 | ||
Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors | Q49679908 | ||
ATM Deficiency Is Associated with Sensitivity to PARP1- and ATR Inhibitors in Lung Adenocarcinoma. | Q50862844 | ||
ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells. | Q50913049 | ||
The long tail of oncogenic drivers in prostate cancer. | Q52611753 | ||
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer | Q58593960 | ||
Measuring recombination proficiency in mouse embryonic stem cells | Q80902088 | ||
Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations | Q91854863 | ||
P577 | publication date | 2020-03-03 | |
P1433 | published in | Cancer Research | Q326097 |
P1476 | title | ATM Loss Confers Greater Sensitivity to ATR Inhibition than PARP Inhibition in Prostate Cancer |
Q101237469 | Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer |
Q97681296 | The genetics of ductal adenocarcinoma of the pancreas in the year 2020: dramatic progress, but far to go |
Search more.